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Abstract
Background: Advances in medical treatment for HIV are driving major changes in HIV policy and practice, including
the encouragement of intake and adherence to HIV antiretroviral treatment (ART) by people living with HIV (PLHIV) for
both personal and public health benefits. However, there is increasing recognition that achieving these goals will
require a concurrent focus on the broader psychological and social wellbeing of PLHIV. Increasingly calls are being
been made to incorporate a stronger focus on quality of life (QoL) of PLHIV into HIV prevention policy.
In order to achieve this goal, HIV community, support and healthcare services need a valid, short and practical way to
evaluate QoL of PLHIV accessing their programs. Current QoL measures are either long, complex, restricted in their use,
or expensive. To address these shortcomings, the PozQoL study aimed to develop, test and validate a short and freely
available scale assessing QoL among PLHIV.
Methods: Drawing on a literature review, the prioritisation of domains and development of the initial pool of items
was conducted in consultation with PLHIV community organisations in Australia. The items covered health concerns,
psychological, social, and functional wellbeing. Testing involved a baseline and a follow-up survey of 465 adult
Australians living with HIV. Participants were recruited through social media and various community organizations
nationwide. The survey included the pilot PozQoL scale and other validated measures of health and wellbeing.
Results: Guided by an Exploratory Factor Analysis and conceptual considerations, a 13-item scale was developed. The
PozQoL scale demonstrated high levels of fit in a Confirmatory Factor Analysis, very good internal consistency, test-
retest reliability, and concurrent validity with other measures that approximated different aspects of QoL.
Conclusion: The PozQoL scale has been tested in a diverse sample of adult PLHIV living in Australia, demonstrating
very good reliability and validity. The insights from PLHIV and other stakeholders supported the balancing of statistical
rigour and conceptual accuracy. The scale is now ready to be implemented and field-tested across a range of
community, support and healthcare programs for PLHIV. This will make a significant contribution to the evaluation and
enhancement of programs for PLHIV.
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Background
Health services, community organisations, and policy-
makers are currently responding to the largest changes in
addressing HIV treatment and prevention for decades. Re-
cent research has demonstrated the effectiveness of modern
antiretroviral treatment (ART) in achieving suppression of
HIV, minimising damage to the immune system while
reducing the risk of onward HIV transmission nearly to
zero [1]. These advances in medical treatment are changing
the experience of living with HIV, and people living with
HIV (PLHIV) are encouraged to seek and adhere to treat-
ment for both personal and public health benefits. This has
led to major changes in HIV policy and practice. Encour-
aging uptake and maintenance of ART by HIV positive
people is now a central plank of national and international
HIV prevention frameworks.
Since 2014, UNAIDS and the World Health Organisa-
tion have championed the 90–90-90 goals striving for
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90% of all PLHIV to know their HIV status, 90% of those
diagnosed to receive sustained ART, and 90% of those
receiving ART to be virally suppressed by 2020 [2, 3].
Yet, there is a growing understanding that achieving
these goals will require a concurrent focus on the
broader psychological and social wellbeing of PLHIV,
both as a means and an end goal. For example, previous
evidence indicates that PLHIV with poor mental health
or experiencing stigma are less likely to adhere to ART
[4–7]. On the other hand, while improving health
outcomes, viral suppression in itself does not ensure im-
proved quality of life (QoL) among PLHIV [7]. For this
reason, calls have been made to incorporate a stronger
focus on QoL into HIV prevention and care policy.
Lazarus and colleagues [8], for instance, have argued for
the fourth 90 – achieving the goal of 90% of PLHIV
reporting good QoL.
Recognizing the importance of QoL for PLHIV, Australian
government included improving QoL of PLHIV among one
of the six objectives of the Seventh National HIV Strategy
2014–2017 [9]. Following recommendations spelled out in
the strategy, many community, health and policy organisa-
tions in Australia have subsequently prioritised improving
the QoL of PLHIV in their programs.
Monitoring QoL among PLHIV posits however some
conceptual and practical challenges. First of all, there is no
consensus as to what QoL is and what key indicators con-
stitute QoL [10]. In addition, according to different exist-
ing definitions, QoL covers a range of domains, such as
physical and mental health, or subjective life satisfaction.
Thus, it cannot be measured with simple measures asses-
sing just one of these elements.
To address this complexity, several existing health-
related quality of life (HRQoL) measures have been val-
idated for PLHIV [11]. These incorporate constructs in
generalised HRQoL measures, such as self-rated phys-
ical and mental health and wellbeing, as well as items
specific to PLHIV, such as the impact of stigma, treat-
ments and HIV symptomatology [11, 12]. However, past
reviews [13, 14] and our analysis have identified that
each of the existing scales has some limitations. Some
scales (e.g., HUI3 [15], EQ-5D [16]) focus too narrowly
on perceived health, neglecting other important aspects
of QoL such as psychological or social wellbeing. Other
scales are modified versions of existing generic scales
(e.g., MOS-HIV [17]), were originally developed for pa-
tients with other conditions (e.g., FAHI; [18]), or were
developed prior to the introduction of HAART (e.g.,
HIV-HOPES [19]), thus might not capture well aspects
unique to current experiences of PLHIV. Similarly, the
existing short generic QoL scales (e.g., SF-12 [20],
AQoL [21], Eurohis QoL [22]) do not tap into all rele-
vant aspects of QoL of PLHIV, particularly issues of so-
cial isolation, resilience, confidence in the future, and
HIV related stigma, which many community and health
programs try to address. The more comprehensive
scales developed specifically for PLHIV, on the other
hand, are rather long (e.g., HIV-HOPES [19], FAHI
[18], PROQOL-HIV [12]) and therefore take a substan-
tial amount of time to complete and are often too large
to be incorporated into short surveys or evaluation
forms. Finally, use of some scales involves licensing
costs or copyright restrictions, which are often insur-
mountable barriers to community-run organizations.
To sum up, none of the existing scales fully meet the
needs of the HIV sector. In consequence, QoL instru-
ments are rarely used in the HIV sector for program
evaluation or monitoring of QoL within day-to-day
health and community service practice.
PozQoL study
HIV community, support, and healthcare services in
Australia expressed a need for an empirically validated,
short and practical way to measure QoL of PLHIV
accessing their programs. To meet this need, the Poz-
QoL study aimed to develop, test and validate a short
and freely available scale assessing the HRQoL among
PLHIV that could be easily incorporated into the day-to-
day practice of health and community services as well as
other community-led social research.
Method
Development of PozQoL
The PozQoL scale was developed in four stages: a re-
view of the existing literature, conceptualization, item
development, and validation. As with many countries,
the Australian response to HIV is characterised by an
active partnership between PLHIV, the community sec-
tor, researchers, clinicians and government [9]. To
maintain this commitment and to deepen the under-
standing of QoL of PLHIV, the PozQoL study was con-
ducted using an approach embedded in the Greater
Involvement of People with HIV/AIDS (GIPA) princi-
ples [23] of a direct partnership with peer-led organisa-
tions representing PLHIV. The term Poz is a colloquial
term used in a number of western countries to refer to
HIV Positive people in the context of empowerment
and self-determination. The term is used primarily by
peer based PLHIV organisations, including those in-
volved in this study. It was incorporated into PozQoL
to reflect the strong PLHIV leadership within the study.
Peer-led organisations were involved in all aspects of
the study, including the conceptualisation and priori-
tisation of the domains, development of items, and de-
cisions concerning the refinement of the final scale.
The aim was to construct a scale that would be easy to
administer and comprehensive, but also limited to no
more than 15 items.
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Conceptualisation of QoL and assessment of domains
A structured literature search was conducted on relevant
databases (Google Scholar, PubMed, Web of Science) to
identify key definitions and domains of HRQoL of PLHIV.
Keywords included “quality of life” in combination with
“HIV” or “AIDS”. Preference was given to more recent
studies (published in 2000 or after), and studies conducted
in Australia and other English-speaking countries.
We found that most definitions agree that QoL refers to
subjective evaluations of one’s life across different do-
mains. However, there was no consensus as to which do-
mains constitute QoL. Based on the definitions we found,
the World Health Organization’s (WHO) definition of
QoL was identified as the most comprehensive and rele-
vant for the purposes of this study:
“[An] individual’s perception of their position in life in
the context of the culture and value systems in which
they live and in relation to their goals, expectations,
standards, and concerns. It is a broad-ranging concept
affected in a complex way by the persons’ physical
health, psychological state, level of independence, so-
cial relationships and their relationship to salient fea-
tures of their environment.” [24]
The literature review formed the basis of consultation with
study partners including PLHIV peer organisations, allow-
ing for articulation of the four key domains. These concep-
tual domains were then ranked by a panel of experts from
PLHIV peer organisations according to their conceptual ac-
curacy, as well as relevance and usefulness to health and
community programs. The four identified domains were
ranked in the following order: 1) psychological domain (in-
cluding mood, coping, hope and fear of the future, and self-
worth); 2) social domain (including personal and social life,
belonging, support, and social stigma); 3) health domain (in-
cluding perception of one’s health, health-related concerns,
energy, and HIV management); and 4) functional domain
(including ability to live a “normal” life, independence,
meaningful occupation, and satisfactory standard of living).
These domains closely resemble the WHO conceptualisa-
tion of QoL with the functional domain effectively incorpor-
ating a level of independence and relationship to the
environment.
Development of items
The initial pool of items was developed by the first four
authors of this article. A large number of candidate
items were developed (over 100 items across the four
domains). The items were pre-tested for face and con-
tent validity through an online survey with a panel of ex-
perts from PLHIV peer organisations (n = 13), and other
HIV experts and stakeholders (n = 5). The panel mem-
bers were asked to assess the relevance of the proposed
items and whether they thought items should be
retained for the next stage of the study. Based on the in-
put from the panel the pool of items was reduced to 64.
Validation study
Study design
To develop and test PozQoL psychometrically, we con-
ducted an online survey of adult Australians living with
HIV, including a one-month follow-up survey to exam-
ine test-retest reliability. The study had the following
aims: 1) to identify scale items for inclusion in PozQoL
and test construct validity; 2) to assess the internal and
test-retest reliability of PozQoL; 3) to examine the con-
current and convergent validity of PozQoL against other
established QoL measures, and measures of health, psy-
chological and social wellbeing.
Data collection
The baseline survey was hosted online between 22
March and 31 May 2017. Participants were invited to
complete a follow-up survey 1 month after they com-
pleted the initial survey. This included a subset of ques-
tions from the baseline survey that enabled assessment
of the test-retest reliability of PozQoL. The baseline sur-
vey was advertised through PLHIV community organisa-
tions and online platforms including Facebook, the
Facebook page of the Institute of Many (an online com-
munity of over 1000 Australian PLHIV), and Grindr
(dating app for gay and bisexual men). Additionally, hard
copies of the survey were distributed through PLHIV
community organisations in Victoria. As an incentive,
participants had the option to enter into a prize draw to
win a tablet computer. Participants were asked to con-
firm that they consent to use their partial data at two
points in the survey. In addition, by the end of the sur-
vey participants were given the option of withdrawing all
their data by ticking an appropriate box.
Those who completed the baseline survey were asked
to provide their email address if they wished to complete
the follow-up survey. These participants were contacted
approximately 1 month after they completed the base-
line. The follow-up survey included the pilot PozQoL
scale and basic demographic information from the base-
line survey. In addition, to control for potential changes
in QoL unrelated to HIV, participants were asked to list
any major changes or events that occurred in the month
leading to the follow-up survey. In both the baseline and
follow-up surveys, participants were asked to provide
their month of birth and the initials of their name,
which enabled us to generate a unique participant code
for matching baseline and follow-up responses while
protecting anonymity. It took participants 33 min on
average to complete the baseline survey and 15 min to
complete the follow-up survey.
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Survey measures
PozQoL
The pilot version of PozQoL including 64 items was used
(see Table 2 for examples of item wording). Participants
scored their response to each item on a 5-point scale (1 -
not at all, 2 - slightly, 3 - moderately, 4 - very, 5 - ex-
tremely). A 5-point scale was chosen to balance sufficient
gradation in responses with psychometric quality.
Other QoL measures
For the assessment of concurrent validity, we selected two
established QoL measures which were previously validated
on PLHIV samples and were freely available (thus could
potentially be used by the community organisations). We
chose one generic and one HIV-specific QoL measure to
verify how well PozQoL corresponds both with broader
and more specific conceptualizations of QoL.
Generic QoL Medical Outcomes Study Short Form-36
(SF-36) [25] is a widely used generic measure of HRQoL,
validated for use with PLHIV [26]. The scale incorpo-
rates 36 items grouped into eight domains, including
physical and mental health (e.g., How much of the time
during the past 4 weeks have you been a very nervous
person?, I am as healthy as anybody I know), as well as
functional wellbeing and role impairment (e.g., During
the past 4 weeks, how much did pain interfere with your
normal work?). Response format and recall period vary
between the items (for most items participants are asked
to report on their QoL in 4 weeks prior to the survey).
Responses were recoded in line with the RAND 36-Item
Health Survey scoring algorithm [27] so that higher
scores indicated a more favourable health state. Subse-
quently, summary scores for the physical (PCS) and
mental component (MCS) were computed and normal-
ized in line with Australian population scoring coeffi-
cients [28]. Correlation between the two composite
scores was r (378) = .88, p < .001.
HIV-specific QoL Functional Assessment of Human
Immunodeficiency Virus Infection (FAHI; [18] Version
4) is an HIV-specific validated measure of HRQoL. The
scale includes 47 items grouped into five domains: phys-
ical wellbeing, functional and global wellbeing, emo-
tional wellbeing/living with HIV, social wellbeing, and
cognitive functioning. Participants rated to what extent
each statement (e.g., I feel fatigued) described their expe-
riences in the 7 days prior to the survey on a 1 (not at
all) to 5 (very much) scale. Responses were recoded so
that higher scores indicated better QoL (α = .97).
Mental health and wellbeing measures
To determine convergent validity, we selected a number
of measures assessing mental health and wellbeing:
Psychological distress Kessler Psychological Distress
Scale (K6) ([29] is used widely in Australia as a screening
measure for depression and anxiety. Participants reported
how often they felt in a particular way (e.g., ‘restless or
fidgety’) in the 30 days prior to the survey on a 1 (all the
time) to 5 (none of the time) scale (α = .93).
Wellbeing The Short Warwick-Edinburgh Mental Well-
being Scale (S-WEMWBS) [30] was used to assess positive
mental health. Participants indicated how much each of the
seven items included in the scale (e.g., I’ve been feeling use-
ful) described their experiences during 2 weeks prior to the
survey, on a 1 (none of the time) to 5 (all of the time) scale
(α = .93).
Satisfaction with life Satisfaction with Life Scale (SWLS)
[31] was used. Participants indicated their agreement with
five items, (e.g., In most ways my life is close to my ideal),
on a 1 (strongly disagree) to 7 (strongly agree) scale (α = .92).
Resilience The Brief Resilience Scale (BRS) [32] was used.
Participants indicated their agreement with six items (e.g.,
I tend to bounce back quickly after hard times), on a 1
(strongly disagree) to 5 (strongly agree) scale (α = .91).
AIDS-related stigma Internalized AIDS-Related Stigma
Scale (IA-RSS) [33] was used. Participants indicated their
agreement with six items (e.g., Being HIV positive makes
me feel dirty) by choosing 1 (agree) or 2 (disagree); (α = .87).
Social support Interpersonal Support Evaluation List
[34]; ISEL-12 version [35] was used. Participants indicated
to what extent each of the 12 statements (e.g., I feel that
there is no one I can share my most private worries and
fears with) was true of them, on a 1 (definitely true) to 4
(definitely false) scale. Responses were recoded so that
higher scores indicated stronger social support (α = .93).
Statistical analysis
Exploratory Factor Analysis (EFA) was used to explore the
underlying factor structure and reduce the number of
items. The final model comprising selected items was
tested in a Confirmatory Factor Analysis (CFA) using a
range of goodness-of-fit measures. Prior to analyses, the
sample was randomly divided into two subsamples for
conducting the EFA and CFA, respectively. Due to the it-
erative nature of the steps in these analyses, the detailed
methods are described in the results section. Inter-item
reliability for the final scale and subscales was assessed
with Cronbach’s alpha. Temporal stability (test-retest reli-
ability) of the scale was assessed among the participants
who completed the follow-up sample, with intraclass cor-
relation coefficients (ICCs). Descriptive statistics including
means, standard deviations, and skewness coefficients of
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the scale were also assessed. Concurrent and convergent
validity was assessed by analysing Pearson bi-variate cor-
relation coefficients between the scale and other QoL,
mental health, and wellbeing measures.
Results
Sample profile
A total of 465 participants living with HIV in Australia
and aged 18 years and older (Mage = 47.26, SD = 11.98)
completed the baseline survey. The sample consisted of
378 men and 14 women (73 participants either did not
answer the question or indicated some other gender).
The majority of men identified as gay (88.4%). Partici-
pants were from all Australian states and territories. Just
under half were university educated (45.6%). The major-
ity lived in urban or suburban areas (78.9%) and were
Anglo-Celtic or European (72.3%) (see Table 1 for a de-
tailed description of the analysed sample). Of this sam-
ple, 149 were contacted for the follow-up survey, with
80 (53.7%) completing the follow-up. Of this group, 51
participants listed no major changes or events occurring
in their lives in the time between the two surveys and
were included in the follow-up sample.
Preliminary analyses
Participants were excluded from the analysis if they had
missing data on more than one PozQoL item (> 1.6%
missing data). Prior to main analyses, the sample from the
baseline study was split randomly into the EFA (n = 270)
and CFA (n = 195) subsamples. Follow up comparisons
did not reveal any significant differences between the two
subsamples with regard to demographic characteristics,
QoL, mental health or wellbeing. Analyses were per-
formed with IBM SPSS Statistics and AMOS 24. The
Keiser-Meyer-Olkin measure of sampling adequacy was
above the recommended value of .60, KMO= .96, and
Bartlett’s test of sphericity was significant: χ2 (2016) =
16,107.90, p < .001. We, therefore, proceeded with an EFA.
EFA
Criteria for EFA were guided by recent theoretical and
practical recommendations for scale development [36–
39]. Both Mardia’s multivariate skewness and kurtosis tests
[40], as well as the Doornik-Hansen test [41] rejected the
null hypothesis of multivariate normality (all ps < .001).
Principal axis factors extraction was therefore chosen over
maximum likelihood extraction as the recommended fac-
tor extraction method for non-normally distributed data
[39]. Because we expected that different domains of QoL
would be inter-related, an oblique rotation (direct obli-
min) was chosen, allowing the factors to be correlated
[37]. Upon obtaining the initial solution, items with low
communalities (< .50; [42]), low primary factor loadings (<
.50; [37]), and high cross-loadings (≥ .32; [43]) were
excluded in an iterative process. The subsequent EFAs
were computed each time items were deleted (11 itera-
tions were used). Thirty-one items were retained in the
final solution (see Table 2 for standardized factor loadings
Table 1 Sample profile (n = 465)
Number Percent
Age
18–34 34 7.3
35–49 157 33.8
50–64 208 44.7
65+ 66 14.2
Education
Secondary/non-university tertiary or below 252 54.3
University educated 212 45.6
Residential location
Inner city 290 62.4
Suburban 77 16.6
Regional/rural 98 21.1
Year first tested positive for HIV
1980–1995 105 22.6
1996–2009 178 38.3
2010–2017 172 37.0
Year started treatment
1980–1995 50 10.8
1996–2009 174 37.4
2010–2017 220 47.3
Treatment status
Currently taking ART 447 96.1
Not taking ART 17 3.7
Most recent viral load test
Undetectable 432 92.9
Detectable 25 5.4
Mean (SD) Possible range
SF-36 PCS 44.30 (11.68) N(50, 10)
SF-36 MCS 41.14 (13.42) N(50, 10)
FAHI 3.63 (0.82) 1–5
K6 3.82 (1.00) 1–5
S-WEMWBS 3.41 (0.87) 1–5
SWLS 4.13 (1.69) 1–7
BRS 3.34 (0.93) 1–5
IA-RSS 0.47 (0.37) 0–1
ISEL-12 2.86 (0.77) 1–4
SF-36 Medical Outcomes Study Short Form-36, PCS Physical Component Score, MCS
Mental Component Score, FAHI Functional Assessment of Human Immunodeficiency
Virus Infection, K6 Kessler Psychological Distress Scale, S-WEMWBS Short Warwick-
Edinburgh Mental Wellbeing Scale, SWLS Satisfaction with Life Scale, BRS The Brief
Resilience Scale, IA-RSS Internalized AIDS-Related Stigma Scale, ISEL-12 Interpersonal
Support Evaluation List
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and communalities for all retained items). Analysis re-
vealed four factors (based on the scree test, eigenvalues >
1; and rejection of factors with fewer than four items [37,
43], which explained 71.8% of the variance. The rotated
factor loadings were 14.36 (factor 1), 9.03 (factor 2), 10.57
(factor 3), and 9.57 (factor 4). Correlations between the
factors ranged from .38 to .65.
Further reduction in the number of items
Results of the EFA were then used as guidance in the
further reduction in the number of items. To preserve
the recommended acceptable minimum of three items
per factor [44], our aim was to narrow down the pool of
items to 12 in the final scale. This decision was driven
by concern for parsimony and the ease of administering
PozQoL. Item reduction followed standard psychometric
criteria for item analysis: mean, standard deviation, cu-
mulated proportion in the two extreme categories, cor-
rected item-total, and between-item correlations were
used to identify items exhibiting floor and ceiling effects
(> 75%), low item-total correlation (< .50) or redundancy
(between-item correlations > .80). Alongside the psycho-
metric criteria, we took into account content validity of
the items, drawing on the research literature and in-
sights from the participation of PLHIV reflected in the
conceptual model. Thus, the final pool included items
Table 2 Exploratory factor analysis structure coefficients and extracted communalities for items assessed for the PozQoL scale
Scale item Communalities (h2) Factor loadings (standardized coefficients)
1 2 3 4
Having HIV prevents me from doing what I want to do 0.78 0.88
Managing HIV disrupts my life 0.74 0.87
Managing HIV gets in the way of my everyday life 0.69 0.84
I feel that HIV prevents me from doing as much as I would like 0.77 0.83
Having HIV prevents me from doing things that are important to me 0.80 0.84
Managing my health disrupts my life 0.72 0.83
Managing HIV wears me out 0.70 0.82
I feel that having HIV limits my capacity to fulfil the different roles I have in life 0.76 0.79
Managing my health gets in the way of my everyday life 0.65 0.76
Having HIV limits my opportunities in life 0.73 0.75
I feel that HIV prevents me from living a normal life 0.81 0.74
Managing HIV is a difficult thing in my life 0.64 0.65
I feel that HIV limits my social life 0.67 0.63
I feel that I am struggling with my health 0.62 0.51
I worry about what people will think of me when they find out I have HIV 0.85 −0.89
I worry about other people finding out I have HIV 0.74 −0.86
I worry that people will treat me unfairly once they learn I have HIV 0.76 − 0.79
I am afraid that people may reject me when they learn I have HIV 0.69 −0.77
I feel ashamed of living with HIV 0.69 −0.73
Having HIV makes me feel inferior to other people 0.63 −0.63
I feel that HIV limits my personal relationships 0.60 −0.55
I am happy with my life 0.80 0.93
I am enjoying life 0.82 0.93
I feel in control of my life 0.73 0.79
I feel that I can deal with whatever comes my way 0.60 0.77
I am optimistic about my future 0.61 0.77
I feel good about myself as a person 0.68 0.77
I worry about the impact of HIV on my health 0.83 0.80
I worry about my health getting worse 0.76 0.79
I fear the health effects of HIV as I get older 0.70 0.76
I worry about my health 0.73 0.63
Items in bold are included in the final scale
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that displayed good statistical qualities and met the con-
ceptual requirements best.
In consultation with the PLHIV peer organisations, we
identified that the criteria employed in the EFA had omit-
ted one important component of the social domain from
the conceptual model, namely ‘belonging’. We, therefore,
retrieved an item from the initial pool, which had good
face validity (I lack a sense of belonging with people around
me) and fulfilled the applied psychometric criteria. Simi-
larly, although our initial goal was to retain three items
per domain, in consultation with the PLHIV peer organi-
sations, we retained the four strongest items for the psy-
chological subscale to maintain content validity for this
domain. The final scale, therefore, comprised 13 items.
CFA
We tested the 13-item scale in a CFA, on the randomly se-
lected CFA subsample (n = 195). The analysis was per-
formed with the maximum likelihood procedures on the
covariance matrix. Items were constrained to each load on
one factor. Goodness-of-fit was assessed with a model chi-
square analysis, the comparative fit index (CFI), standardized
root-mean-square residual (SRMR), and the root-mean-
square error of approximation (RMSEA). The following
guidelines were used for optimal fit (Hu & Bentler, 1999):
p > .05 for the model chi-square; CFI > .95; SRMR < .08;
RMSEA < .06. The four-factor solution achieved excellent
levels of fit: Χ(61)
2 = 74.42, p= .116; CFI = .992, SRMR= .036,
RMSEA= .034 [.000, .059]. Figure 1 shows results from the
CFA, including standardized pattern coefficients for each
item, all of which were above .70 (values ranged from 0.73
to 0.89).
Internal consistency and test-retest reliability
Thirteen items retained in the final PozQoL scale are
displayed in Table 3. All corrected item-total correla-
tions exceeded 0.60 (range = 0.65–0.80), all inter-item
correlations were below 0.80 (average homogeneity
index = 0.58; range = 0.40–0.79).
Inter-item reliability (assessed with Cronbach’s alpha)
for the PozQoL was α = 0.95 [95% CI: (.93 to .96)], indi-
cating excellent internal consistency. Reliabilities for par-
ticular subscales were as follows: α = 0.91 [95% CI: (.89
to .93)] - health concerns; α = 0.91 [95% CI: (.89 to .93)]
– psychological; α = 0.82 [95% CI: (.77 to .86)] – social;
and α = 0.87 [95% CI: (.84 to .90)] - functional.
Temporal stability (test-retest reliability) of the scale was
assessed among the 51 participants who comprised the
follow-up sample. Intra-class correlation coefficients
(ICCs) were computed between baseline and follow-up
scores based on a one-way random effects model. Scores
on the PozQoL displayed high levels of stability, ICC = 0.
95 [95% CI: (.92 to .97)]. Similarly, stable results were ob-
tained on scores for all subscales: ICC = 0.91 [95% CI: (.85
to .95)] - health concerns; ICC = 0.85 [95% CI: (.74 to .92)]
– psychological; ICC = 0.83 [95% CI: (.71 to .91)] – social;
and ICC = 0.89 [95% CI: (.80 to .93)] - functional.
Score construction
Scoring PozQoL was a two-step process. First, all
negatively-worded items were recoded so that higher scores
for all items indicated better QoL. Subsequently, items were
averaged to create the total score and scores for each sub-
scale. The response range for each scale was 1–5. Items
with missing responses were not taken into account when
calculating the scores. (Only responses of participants who
missed none or one item were used to compute the scores.
Missing data for each participant varied between 0 and 7.
7%; missing data for each item varied between 0 and 0.9%).
Thus, the scores represented the average for items in the
subscale that the respondent answered.
Scale properties of the PozQoL
Means and standard deviations were M = 3.43 [95% CI:
(3.35 to 3.51)] for the total PozQoL score, M = 3.22 [95%
CI: (3.12 to 3.33)] for the health concern subscale, M =
3.38 [95% CI: (3.29 to 3.47)] for the psychological sub-
scale, M = 3.27 [95% CI: (3.16 to 3.37)] for the social
subscale, and M = 3.88 [95% CI: (3.79 to 3.98)] for the
functional subscale, respectively. Diagnostic plots, in-
cluding histograms and a standardized normal probabil-
ity plot, indicated that PozQoL scores were moderately
skewed, with a skewness coefficient of −.53. Skewness
coefficients for the subscales varied between −.27 and
− .93, indicating either an approximate symmetry or a
moderate skew.
Concurrent and convergent validity
Table 4 displays Pearson bi-variate correlation coeffi-
cients between the PozQoL and other QoL, mental
health, and wellbeing measures. Correlation coefficients
of .30–.49, .50–.69, and > .70 were interpreted as small,
moderate, and large, respectively.
Concurrent validity was determined by assessing correl-
ation coefficients between PozQoL and other measures of
QoL. We expected that PozQoL would correlate positively
both with a generic and an HIV-specific measure of QoL.
Given that PozQoL was designed specifically for PLHIV,
we expected the relationship with the latter to be stronger.
The total score for PozQoL displayed a significant moder-
ate correlation with the physical component of SF-36 and
a strong correlation with the mental component of SF-36.
Similarly, PozQol displayed a strong correlation with
FAHI, indicating a high level of agreement between the
measured concepts. As expected, the correlation be-
tween PozQoL and FAHI was stronger than the correl-
ation with the SF-36 composite scores (z = 7.10, p < .001
for PCS and z = 4.41, p < .001 for MCS, respectively).
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Convergent validity was assessed with correlation coef-
ficients between PozQoL and other measures of mental
health and wellbeing. The total score for PozQoL dis-
played significant moderate to strong correlations with
all measures.
Discussion
Community and health services in the HIV sector
expressed a need for an empirically validated instrument
that measures the impact of programs on QoL among
PLHIV. The development of a short easy to use instrument
could transform the way HIV organisations, governments,
and other stakeholders evaluate clinical and support pro-
grams, allowing these to be more firmly evidence-based
and consistent across the sector.
In this study, we developed and tested a brief 13-item
PozQoL scale assessing QoL among PLHIV. PozQoL
displayed excellent construct validity and very good re-
liability, including consistency and temporal stability.
The factor structure of the PozQoL scale is consistent
with the conceptualization of QoL proposed by the
World Health Organization [24] including four key fac-
tors: 1) health concerns; 2) psychological; 3) social; and
4) functional domains.
An assessment of concurrent and convergent validity
indicated a significant overlap between PozQoL and two
other established measures of QoL, and consistent cor-
relations with other measures of mental health and well-
being. Thus, PozQoL may be considered a shorter
alternative to the use of multiple larger scales. The active
partnership with PLHIV peer-led organisations enabled
the study to ensure the research rigour was complemen-
ted by practical and conceptual considerations and con-
tributed a deeper understanding of the complexity of the
experience of PLHIV.
Based on feedback from stakeholders we believe the Poz-
QoL scale may be useful in several ways, including evalu-
ation of health and support programs for PLHIV, and as an
indicator or assessment of HRQoL of PLHIV in research
studies. The brevity of PozQol will enable the inclusion of
HRQol in broader surveys of PLHIV, and facilitate com-
parison of HRQoL between groups of PLHIV with different
needs and experiences, or at different stages of the con-
tinuum of care (diagnosis, treatment uptake, treatment ad-
herence, viral suppression). Being brief and freely available
also means that PozQol can be used in the evaluation of
programs designed to improve QoL and treatment
Fig. 1 CFA of 13 items from the PozQoL scale
Table 3 The PozQoL scale
I. health concerns
1. I worry about my health
2. I worry about the impact of HIV on my health
3. I fear the health effects of HIV as I get older
II. psychological
4. I am enjoying life
5. I feel in control of my life
6. I am optimistic about my future
7. I feel good about myself as a person
III. social
8. I feel that HIV limits my personal relationships
9. I lack a sense of belonging with people around me
10. I am afraid that people may reject me when they learn I have HIV
IV. functional
11. I feel that HIV prevents me from doing as much as I would like
12. Having HIV limits my opportunities in life
13. Managing HIV wears me out
“This survey is intended for people living with HIV. We would like to ask you
about your health, relationships, life satisfaction, and wellbeing. Please indicate
how much the following statements apply to you on a scale from 1 – not at
all to 5 – extremely.” 1 – not at all 2 – slightly 3 – moderately 4 – very 5
– extremely
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maintenance for PLHIV. This includes the capacity to
monitor total and individual domain scores, particularly
when a program may be focused on one or two of the do-
mains. Incorporating QoL into service evaluation which
otherwise would not be able to include a large scale may
support the targeting of programs and services to meet and
sustain the 90, 90, 90 goals. An implementation trial of the
PozQoL scale will be conducted across clinical, community
and peer-led programs in 2018.
Limitations
Although our results indicate that PozQoL is a valid meas-
ure of QoL among PLHIV, the current study had several
limitations. While the sample was diverse, the majority
were Anglo-Australian gay-identifying men. Although this
demographic group constitutes the vast majority of
PLHIV in Australia [45] and so was to be expected, future
research may be needed with larger samples of other gen-
ders, sexualities, and cultural backgrounds to confirm its
applicability and reliability. Similarly, only Australian par-
ticipants were involved in the study. Future research may
be needed to test the PozQoL scale among PLHIV in
other English-speaking countries, and to assess its capacity
to be translated into other languages.
The majority of the sample was collected online and
through community organizations and networks. It is feas-
ible that our sample was not entirely representative of the
PLHIV population in Australia, particularly individuals not
connected with HIV services and community organisations.
Further, due to the nature of our study, the final 13-
item PozQoL scale was not tested on its own, but as part
of the wider set of 64 items. Future studies are thus
needed to confirm the validity of the PozQoL as a stan-
dalone measurement tool.
Given the development and validity trial was cross-
sectional, we have yet to assess the PozQoL scale’s sensitiv-
ity to detecting changes in QoL over time. The study will
be implementing a usability and sensitivity implementation
trial in 2018 across a range of health and community ser-
vices in Australia. The PozQoL will also be trialled in cross-
sectional studies in the USA, which due to the nature of
the epidemiology, will enable us to test validity of the scale
in more gender-, sexually-, ethnically-, and language-
diverse samples than in Australia. For the purpose of the
studies the PozQoL will be translated into Spanish.
Conclusion
The PozQoL scale has been tested in a diverse sample of
adult PLHIV living in Australia, demonstrating very
good reliability and validity, as well as the strength of
meaningful involvement of people with HIV in research
studies. It is recommended that the scale is implemented
and field-tested across a range of community, support,
and healthcare programs for PLHIV and in other coun-
tries. This will make a significant contribution to the so-
cial research on PLHIV and the evaluation of programs
for PLHIV.
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